Pieris reaches key milestones under the collaboration agreement with Syngenta

Freising-Weihenstephan, Germany (ots) - July 6th 2006. Pieris AG,
a biopharmaceutical and protein engineering company exploiting its
proprietary Anticalin® technology for the development of superior
human biotherapeutic and diagnostics products, today announced that
it has successfully reached key milestones within its collaboration
project with Syngenta.

After careful evaluation of the identified Anticalins® with
respect to the specific needs for a highly efficacious therapy as
well as commercial factors, both companies came to the conclusion
that the Anticalins® identified by Pieris clearly fulfil the
requirements for preclinical and clinical development within the
undisclosed indication.

"The accomplishment of these key milestones under the agreement
with Syngenta is another clear proof that our Anticalin® technology
is delivering engineered protein therapeutics highly suited to be
used as biopharmaceuticals," remarked Dr. Andreas Hohlbaum, Director
of Science and Preclinical Development at Pieris. "In addition to its
business strategy this achievement clearly validates Pieris as a
reliable collaboration partner and will serve as a basis for other
partnering activities in the near future," said Pieris' Chief
Executive Officer Evert Küppers.

ENDS

For further information, please contact:

Pieris AG
Dr Andreas Hohlbaum, Director of Science & PD,
Phone +49 (0) 8161 1411 400

Notes to editors:

About Pieris AG
Pieris is a biopharmaceutical company engaged in the discovery and
development of Anticalins® for the diagnosis and treatment of
life-threatening human disorders. Exploiting extensive know-how in
protein engineering as part of a broad intellectual property
portfolio, the Company applies a balanced risk business model to the
development of its Anticalin® candidates. Recognizing the enormous
market potential of protein-based drugs, Pieris is committed to
becoming an integrated drug discovery and development company and
expects to file an IND application for its first therapeutic
Anticalin® at the beginning of 2008.
Further information is available at http://www.pieris-ag.com

Anticalin®, Anticalins® are registered trademarks of Pieris
Proteolab AG.

About Syngenta

Syngenta is a world-leading agribusiness committed to sustainable
agriculture through innovative research and technology. The company
is a leader in crop protection, and ranks third in the high-value
commercial seeds market. Sales in 2005 were approximately $8.1
billion. Syngenta employs more than 19,000 people in over 90
countries. Syngenta is listed on the Swiss stock exchange (SYNN) and
in New York (SYT).
Further information is available at www.syngenta.com.

This press release may contain projections or estimates relating
to plans and objectives regarding our future operations, products, or
services, future financial results or assumptions underlying or
relating to any such statements. Each of these projections or
estimates constitutes a forward-looking statement subject to risks
and uncertainties, many of which are beyond our control. Actual
results could differ materially depending on a number of factors,
including the timing and effects of regulatory actions, the results
of clinical trials, the company's relative success in developing and
in gaining market acceptance for any new products, and the
effectiveness of patent protection.

Originaltext: Pieris ProteoLab AG
digital press kits: http://presseportal.de/story.htx?firmaid=61954
press kits via RSS: feed://presseportal.de/rss/pm_61954.rss2

Contact:

Dr Andreas Hohlbaum, Director of Science & PD,
Phone +49 (0) 8161 1411 400